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ABSTRACT
Individuals having Genetic Thrombophilia pose a higher risk of having a thrombotic
event. It is crucial to determine these gene variants to prevent a possible episode of
thromboembolism. With the current PCR method, it involves individual processing of DNA
isolation, amplification, and detection using three (3) different instruments resulting to an
increased turnaround time of 5 to 7 days and additional staff utilization. It is performed by
repetitive manual sample pipetting and preparation of reagent master mixes in small vials.
Results interpretations are entered manually to a worklist built initially for final verification.
These processes increase the risk of staff injury and potential result error that could impact
patient management.
The introduction of the GeneXpert technology by Cepheid will aid in the prevention of
staff injury from repetitive motion, improve the turnaround time and eliminate potential risk of
error. This test system performs DNA isolation, amplification and detection within a cartridge kit
that will decrease instrument preventive maintenance costs and personnel hands-on utilization.
Furthermore, an individualized quality control plan (IQCP) will be implemented after risk
assessment of the pre-analytic, analytic and post-analytic phase of testing to customize quality
control frequency ensuring the accuracy of test results upon approval by the Laboratory director.
A combination of 104 whole blood samples of sodium citrate (83) and EDTA (21) that
were previously tested with the current method was used for the validation study. Fifteen (15) of
the whole blood citrate samples were frozen after testing to confirm the manufacturer's claim of
an alternative sample. Seventy-nine (100%) whole blood citrate samples and twenty-one (100%)
whole blood EDTA samples were correlated with the results of the current PCR method.
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INTRODUCTION
Genetic thrombophilia is the most common hereditary disorder that increases the
likelihood occurrence of thrombosis. It can be identified with a significant minority of patients
with venous thromboembolism and in most patients with well-known thrombotic episodes
(Murin, Marelich, Arroliga, & Matthay, 1998).
There are also other endogenous anticoagulant deficiencies such as Protein C, Protein S
and Antithrombin that have been determined to cause hypercoagulable state, but the incidence is
low with patients with familial thrombosis. As a result of extensive research and study, it was
discovered that resistance to activated protein C (APC) is the most common genetic risk factor
for venous thrombosis. It is caused by a single point mutation in the factor V gene. A gene that
transcribes the protein called coagulation factor V. These coagulation factors is a group of
related proteins that make up the coagulation system that is responsible for the formation of
blood clots after an injury and trigger blood vessel repair (Genetics Home Reference, n.d.).
Another important type of hereditary thrombophilia is a variant that occurs in the prothrombin
gene at allele 20210 (PT20210), its prevalence and association of thrombosis is not as high
compared Factor V Leiden but is significant. The most common clinical manifestation is deep
vein thrombosis (DVT) thus, the increased ability to determine underlying risk factors with
thrombotic patients will enable to perform immediate testing with these genetic variants.
The detection of the Factor V Leiden mutation and PT20210 allele are best performed
using point mutation real-time PCR analysis due to technique simplicity and allows
differentiation from rare variants (Peter C. Cooper & Anne C. Goodeve, 2012).
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ACTIVATED PROTEIN C RESISTANCE (FACTOR V LEIDEN)
The factor V allele is resistant to the
proteolytic effect of Protein C in patients with
activated protein C resistance. This resistance
is due to the transition of guanine to adenine at
nucleotide position 1691 (G1691), a gene
product called Factor V Leiden. The single
FIGURE 1 SIMPLIFIED COAGULATION CASCADE &
PROTEIN C ANTICOAGULATION SYSTEM

point mutation in the Factor V gene resulting in a
substitution of arginine with glutamine at position

506 in one of the protein cleavage sites and renders activated Factor V resistant to cleavage and
the inability to deactivate Factor V and Factor VIII in the coagulation cascade causing increased
formation of thrombin resulting to clot formation. (Figure 1).
The presence of this mutation will result in a 5-10fold increase for heterozygote carriers
and approximately 50 -100fold in homozygotes risk of venous thrombosis which occurs 20-60%
of APC resistant individuals. The FV mutation is prevalent from 1-15% in a population of
Caucasian origin (Zöller, Hillarp, Berntorp, & Dahlbäck, 1997).
PROTHROMBIN 20210A MUTATION
The activation of Factor V and Factor VIII by precursor prothrombin converts fibrinogen
to fibrin. It has been identified the transition from guanine (G) to adenine (A) at the last
nucleotide position 20210 in the 3’- untranslated region of the gene (figure 2) that is associated
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with an increased risk for venous
thrombosis. Having the 20210A allele
causes marked increase levels of
plasma prothrombin. (Poort SR, 1996)
Heterozygotes have a 2-5fold
FIGURE 2 G (20210) A PROTHROMBIN GENE

increase risk of thrombosis and with the presence

of other forms of thrombophilia will significantly increase thrombotic risk. Homozygotes are
rarely occurring in less than 1% of the population.
Historically, laboratory testing for thrombophilia focuses on the detection of the
endogenous anticoagulant deficiencies of Protein C, Protein S and Antithrombin,
dysfibrinogenemia and antiphospholipid antibodies (APA)/lupus anticoagulants (LA) but for the
past decade, venous thromboembolism has been so complex that because of its heterogeneity,
diagnosis is dependent on both acquired and genetic factors. In this regard, the mutation
determination of FV Leiden and PT20210 gene is highly significant in the pathogenesis of DVT
in combination with acquired factors such as trauma, pregnancy, surgery, age, weight, etc.
Coexistence of both mutations of Factor V Leiden and PT 20210 are found in 10% of the
population with predetermined thrombotic episodes. (Vicente R et al, 1999)

4

MATERIALS AND METHODS
INSTRUMENTATION
An FDA approved, closed platform GeneXpert system by
Cepheid (Figure 3) that performs qualitative real-time PCR
for automated detection and genotyping of Factor
V Leiden and PT20210 alleles directly from whole blood
samples. The test is intended to perform DNA isolation,
FIGURE 3 GENEXPERT SYSTEM

amplification, and detection in a cartridge kit with a

turnaround time of 30 minutes for each testing. A sample volume of 50ul of whole blood is
dispensed straight into the bottom of the cartridge. Each cartridge (Figure 4) includes internal
quality controls and contains freeze-dried beads with necessary components for PCR such as
DNA polymerase, nucleotides, primers and scorpion probes. Through the PCR cycles, the
specific binding of the probe sequence to the target mutation detected at real time and allows the
software to report out both FV and PT20210 in approximately thirty-two (32) minutes.

FIGURE 4 CARTRIDGE KIT
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VALIDATION STUDY
A combination of 104 whole blood of sodium citrate and EDTA samples that were
previously tested using current invader assay method was processed with the GeneXpert
technology system. Most of these samples were stored at 2-8C and stable for 15 days and some
samples were stored at room temperature with a 24hour stability. Additionally, 15 frozen citrate
samples were tested to verify its suitability for testing as recommended by the manufacturer.
Precision studies consist of four (4) Sodium citrate samples consisting of one (1) normal
sample for both FV Leiden and PT20210, one (1) heterozygous sample for PT20210, one (1)
heterozygous sample for FV Leiden and one (1) homozygous sample for both FV Leiden and
PT20210. These 4 samples were run in duplicate for 5 days.
Correlation studies were performed with eighty-five (85) whole blood samples, a
combination of sixty-four (64) citrate tubes and twenty-one (21) EDTA samples. The samples
included two (2) homozygous FV Leiden, one (1) homozygous PT20210, thirty-seven (37)
Heterozygous FV Leiden, thirty-one (31) normal FV Leiden, seventeen (17) heterozygous
PT20210 and fifty-one (51) normal PT20210. Fifteen (15) frozen citrate samples were also tested
for possible consideration of using this type of sample for testing as stated by the manufacturer.
INDIVIDUALIZED QUALITY CONTROL PLAN
According to the Clinical Laboratory Improvement Amendments (CLIA) of 1988,
laboratories are required to have Quality Control procedures to monitor the accuracy and
reliability of test results. A minimum of 2 levels of controls must be performed every eight hours
of patient testing. IQCP provides a foundation for an alternative quality control (QC) program
that would allow laboratories, after appropriate assessment, the choice to implement a
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customized QC plan for specific tests utilizing internal control systems. By performing the steps
of IQCP, it will evaluate the potential sources of error in the three (3) phases of testing and
establish an appropriate QC and best practices to prevent possible errors. After the evaluation
process, other potential sources of error might be determined and that may require additional QC
activities resulting in a more comprehensive QC program.
IQCP consists of 3 parts: Risk assessment (RA), Quality control plan (QCP) and Quality
Assessment (QA).

1.RISK ASSESSMENT (RA)
Identification and evaluation of the risk that occurs in the preanalytical, analytical and
post-analytical phases of testing. There are six (6) components that need to be evaluated for Risk
assessment for potential sources of error and possible failures. These are Specimen, Test System,
Reagents, Environment, Testing personnel, and Test results.
Lists of information to conduct Risk Assessment (RA)


Laboratory policies and procedures



CAP Checklists- Common Checklist and Molecular Pathology



Manufacturer’s package inserts (intended use, reagent, QC frequency, maintenance,
environment, et al)



Method Validation records



Laboratory records (QC, PT, New lot verification, Maintenance)



Error correction and Provider complaints



Personnel Training and competency records
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Based on the information listed, a table summary of Risk assessment (Table 7) was
established for possible sources of error or failures consisting of the six (6) elements in
relation to the different phases of testing. It is evaluated according to Risk level (Table 1) and
Risk acceptability (Table 2).
TABLE 1 DETERMINATION OF RISK LEVEL
Frequency of Occurrence
Unlikely (once every 2-3 years)
Occasional (once every year)
Probable (once per month)
Frequent (once a week)
*Unknown (detectable but the frequency is
unknown
**Undetectable (unable to detect)

Severity of Harm
Negligible (temporary discomfort)
Minor (temporary injury; not requiring
medical intervention
Serious (impairment, requiring medical
intervention
Critical (life-threatening consequences)

*Unknown = Frequency of occurrence is unknown. No documentation/data collected.
**Undetectable = Unable to detect error unless by direct observation. (e.g. improper collection)
TABLE 2 RISK ACCEPTABILITY MATRIX
Probability of
Harm
Frequent
Probable
Occasional
Unlikely
Unknown
Undetectable

Negligible

Minor

Serious

Critical

Not Acceptable
Acceptable
Acceptable
Acceptable
Not Acceptable
Not Acceptable

Not Acceptable
Not Acceptable
Acceptable
Acceptable
Not Acceptable
Not Acceptable

Not Acceptable
Not Acceptable
Acceptable
Acceptable
Not Acceptable
Not Acceptable

Not Acceptable
Not acceptable
Not acceptable
Acceptable
Not Acceptable
Not Acceptable

2. QUALITY CONTROL PLAN
A Quality Control Plan (QCP) describes practices, procedures, and resources needed by
the laboratory to ensure the quality of a testing process. The QCP includes measures to assure the
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accuracy and reliability of test results, and that the quality of testing is adequate for patient care.
The QCP must provide for immediate detection of errors that occur due to test system failure,
adverse environmental conditions, and operator performance. It must also monitor, over time, the
accuracy and precision of test performance that may be influenced by changes in the specimen,
test system, reagent, environment, or variance in operator performance.
This QCP is fulfilled through the creation of written standard operating procedures for
instrumentation, maintenance, quality assurance and reviews involving historical quality control
review, historical proficiency testing review, test system information and all the information used
to conduct the risk assessment.
Each cartridge contains internal controls that check every step of the assay that validates
the system, test reagents, sample, lysis, amplification and integrity of the cartridge itself.
External controls were purchased from Maine molecular Quality control Inc and were run thru a
31-day period (College of American Pathologist, Common checklist, n.d.). It is used to verify the
accuracy and precision of the Cepheid GeneXpert analyzer. In an unopened bottle of external
controls, it will last until the indicated expiration date when stored at 2C – 8C. In an open bottle,
the controls were stable for 30 days. In the event of any QC failure, QC must be repeated with
appropriate documentation and corrective action performed. A patient look-back will be
performed if QC continues to fail and will immediately be addressed to Manufacturer’s technical
support for evaluation. For repeated results that are not in agreement, an error correction report
will be performed, appropriate investigations and corrective actions will be implemented to
verify instrument performance and accuracy of results.
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3. QUALITY ASSESSMENT (QA)
Quality assessment is a continuous process of monitoring the effectiveness of the Quality
control plan for error prevention and detection. QCP and QA will be updated when new sources
of errors or failures are identified. Non-conformance and/or procedure deviation will be
addressed with affected personnel by the laboratory management for appropriate corrective
action(s). A review system mechanism will be established that details ongoing activities for
monitoring the effectiveness of the QCP. The mechanism of Quality assurance includes:


Verification of new lot reagent kit -test with 5 patient samples paralleled against
a current lot of reagent with results within acceptable criteria.



Training of personnel- completed all the applicable training checklists and
comprehension of test procedures, signed off by Quality supervisor/manager



Competency Assessment- performed at initial orientation, after 6 months and
annual evaluation.



Proficiency Testing- Performance of PT survey (TPM from CAP) includes
handling by staff and PT failure investigation if needed.



Error Correction reports (ECR) -Refer to the specific binder



Medical record or Test error correction request



Physician inquiries- document any clinician concern/or feedback



Population statistics- Monthly report compared with historical statistics and
maintained in quality control indicator folder. Acceptable criteria are 2 SD of
historical results.
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RESULTS
The precision or reproducibility study consisted of four (4) sample types: one (1) sample
normal for both FV Leiden and PT20210, two (2) samples for each heterozygous FV Leiden and
PT20210 and one (1) homozygous type for both FV Leiden and PT20210. These samples were
run in duplicate for 5 days and were all 100% in agreement with the expected result (Table 3).
For the accuracy study, a combination of sixty-eight (68) Sodium Citrate and EDTA samples
were used for correlation, all results obtained were 100% in agreement with the results of the
previous method. (Table 4)
Table 3 Precision Summary in duplicates x 5 days
Specimen ID
Normal (FVL
/PT20210
Heterozygous (FVL)
Heterozygous
(PT20210)
Homozygous
(FVL/PT20210)

Obtained result
Normal/Normal

Expected Result
Normal/Normal

% Total Agreement
100% (10/10)

Heterozygous

Heterozygous

100% (10/10)

Heterozygous
Homozygous/
Homozygous

Heterozygous
Homozygous/
Homozygous

100% (10/10)

Obtained result
Homozygous (2/2)
Homozygous (1/1)

Expected Result
Homozygous
Homozygous

% Total agreement
100%
100%

Heterozygous (37/37)
Heterozygous (17/17)

Heterozygous
Heterozygous

100%
100%

Normal (31/31)
Normal (51/51)

Normal
Normal

100%
100%

100% (10/10)

TABLE 4 CORRELATION SUMMARY
Specimen
Homozygous (FVL)
Homozygous
(PT20210)
Heterozygous (FVL)
Heterozygous
(PT20210)
Normal (FVL)
Normal (PT20210)
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With the additional fifteen (15) frozen samples, thirteen (13) samples correlated with
previous verified results, two (2) samples were interpreted as invalid probably due to gross
hemolysis and/or loss of integrity. A frozen sample is unlikely to be used primarily because
serum or plasma is the preferred sample for testing.
The overall accuracy and precision performance of GeneXpert technology using whole
blood sodium citrate and EDTA samples demonstrate 100% agreement with the predicate
method, Invader chemistry. Cepheid GeneXpert yielded a 98.06% performance agreement with
the inclusion of frozen samples for a possible alternative sample type but determined not to be
used.
IQCP SUMMARY
The implementation of IQCP for the detection of both the FV Leiden and PT20210
mutation using GeneXpert technology will assure the accuracy of the test result through the
assessment of the pre-analytical, analytical, post-analytical phases of testing. The risk assessment
outcome involving the six (6) components suggest probable risk occurring during pre-analytical
testing such as mislabeled specimens, sample contamination, and personnel competency (Table
5). This risk can be mitigated through adequate personnel training, the creation of appropriate
procedure with emphasis on correct sample requirement and adherence to daily, weekly and
monthly maintenance guidelines
External Quality control was also evaluated for the span of thirty-one (31) days for the
determination of a customized plan to modify quality control frequency. It is used to assess
instrument performance, the stability of cartridge kits and to save cartridge costs. Controls
consist of normal, heterozygous and homozygous types. A total of 25 results were reviewed and
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demonstrated no QC failure or within an acceptable performance, therefore the established
customized external QC frequency will be set to perform every 31 days which is based on the
College of American Pathologist (CAP) common checklist guideline, for every new lot of
reagent kit, every new shipment of reagents and for any needed troubleshooting purposes.
Furthermore, the implementation of a quality assessment program will review all activities
mentioned in the IQCP and provide corrective actions, as needed, in order to measure its
effectiveness and modification in the case of new errors that are detected or identified. (Table 7)
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TABLE 5 RISK ASSESSMENT SUMMARY
Frequency of
Occurrence

Phase

Severity

Possible Sources of Error
1.0 Specimen

Risk
Acceptable
Y/N

Preanalytical

Mitigations

Occasional

Preanalytical

Minor

Y

Occasional

Preanalytical

Minor

Y

1.4 Transport

Occasional

Preanalytical

Minor

Y

1.4 Integrity
2.0 Reagents
2.1 Receiving and Storage

Occasional

Analytical

Minor

Y

Delta check,
history
Adhere to
guidelines
detailed in the
procedure
Rejection
criteria-refer
to SOP/
Training
Redraw
sampleRemedial
actions for
mishandling
Repeat/redraw
sample

24hour
temperature
monitoring

1.1 Mislabeled sample

1.2
Collection/Container/Volume

1.3 Improper Storage

Probable

Serious

N

Occasional

Preanalytical

serious

Y

Unlikely

Preanalytical

Minor

Y

Unlikely

Analytical

Negligible Y

2.2 Expiration Dates

2.3 Quality Control

Replace kit
the system will
not run/ visual
inspection
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Frequency of
Occurrence

Phase

Severity

Risk
Acceptable
Y/N

Possible Sources of Error

Mitigations

3.0 Testing Personnel

3.1 Training &
Competency Assessment

3.2 Labeling & Cartridge
handling
3.2 Proficiency TestingFailure due to Instrument
Malfunction

3.2.1 CAP PT procedure
not followed/PT not
handled in the same
manner as a patient
sample

3.3 Staffing- Inadequate
to perform testing

Probable

Analytical

Serious

N

Occasional

Pre-analytical

Minor

Y

Unlikely

Analytical

Unlikely

Y

Annual
Competency
Evaluation and
monitoring
Direct
observations of
handling,
Competency
Evaluation
All PT failures
are addressed
and investigated

Y

Provision of
instruction to
testing
personnel/
signed an
attestation form

Y

Sample can be
stored for 15
days w/ temp.
monitoring

Occasional

Unlikely

Analytical

Analytical

Negligible

Negligible

Frequency of
Occurrence

Phase

Severity

Risk
Acceptable
Y/N

Possible Sources of Error
4.0 Test system
4.1 Contamination

Unlikely

Analytical

Negligible

Y

4.2 System errors- Pressure,
air bubbles, temperature,
optical signal,
communication

Occasional

Analytical

Negligible

Y

4.3 Defective Cartridge

Occasional

Analytical

Negligible

Y

4.5 Defective modules

Occasional

Analytical

Negligible

Y
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Mitigations

Remove and; used
new
cartridge if
necessary

System checks;
Follow maintenance
procedure
Visual Check, Repeat
with new cartridge
kit
Disable the module;
Call Technical
support

5.0 Environment

5.1 Temperature/airflow/
humidity/ventilation

Unlikely

Pre-analytical

Negligible

Y

5.2Sample/Amplicon
Contamination

Unlikely

Pre-analytical

Serious

N

5.3 Maintenance

Unlikely

Pre-analytical

Negligible

Y

5.4 Electric

Unlikely

Pre-analytical

Negligible

Y

5.5 Defective Cartridge
6.0 Test Results

Occasional

Analytical

Negligible

Y

Appropriate
environmental
conditions
maintained
Procedure for
proper
decontamination
Criteria defined in
procedure
Connected to UPS
power supply
Visual check,
Internal control
failure “Invalid”

6.1 Review results

Unlikely

post-analytical

Minor-Critical

Y

6.2 Providers Complaints/
Inquiries

Unlikely

post-analytical

Minor

N

Auto-transmission
of results/delta
check
Investigate/Review
IQCP/Modify

6.3 Release of results

Unlikely

Post-analytical

Negligible to
serious

N

Criteria defined in
procedure
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TABLE 6 SUMMARY OF QCP
Type of Quality Control
Testing of appropriate
external QC before or
concurrently when in use

Instrument Preventive
maintenance

Room Temperature check
Refrigerator Temp check
Inter-instrument correlation

User training/Competency

PT assessment survey- TPM

Frequency
 Each new lot
 Each new shipment
 Monthly
 PM/software upgrade



Daily (each day of
use)
 Weekly and as needed
 Monthly and as
needed
24/7 continuous monitoring
Every 6 months


Each new user and
users prone to errors
Initial, 6 months and annual
Two- Three
times/year

Criteria for Acceptability
Results are within specified
QC range
Any QC failure is
investigated immediately,
addressed by the QC CLS to
QC Manager and/or
Supervisor
Meet acceptable criteria as
defined in the Cepheid
maintenance section

20-25 degrees C
2-8 degrees C
Correlation of test result and
External QC testing on both
GeneXpert instrument
Training checklist completed
Pass all 6 elements of
assessment
>80% score
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TABLE 7 SUMMARY OF QA ACTIVITY

Frequency
Daily

Weekly
Monthly

Annually

As needed

QA Activity
Daily review of the patient's result for reporting errors and/physician
complaints. Investigate and initiate occurrence management report (OMR)
Confirmation of successful result transmission. Review BRL
Monitor Review queue for aberrant/unusual results.
Audit GeneXpert PM charts for compliance
Review any new lot or shipment QC, as applicable
Review monthly QC Data. Initiate corrective action(s) and revise QCP when
unexpected QC failures indicate an adjustment to the QC plan defined.
Review Isensix temperature logs and perform corrective actions when
indicated, appropriately documented.
Review of all equipment maintenance/ monitoring logs according to SOP
Review PT Scores and evaluate shift trends. Initiate corrective action as
needed
Perform regular training and user competency assessment based on protocols,
modify if necessary
Monitor pre-analytic quality indicators that address specimen handling and
erroneous specimen labeling. Take corrective action needed
Review manufacturer’s instruction for any changes or updates
Confirm current procedure are available to users
Confirm procedure accuracy and clarity
Update procedures, training checklist and/or competency form
Follow up on complaints; Investigates the root cause(s) of error correction
Examine reasons for QC failures, PT failures and patient isolate reporting
errors and address, as needed, in a new/updated risk assessment: 1) Has a new
risk factor been identified? 2) Does this change the frequency of risk? 3) Does
the risk change the potential severity of harm of patient?

COSTS SAVING
Preventive Maintenance cost- The elimination of seven (7) instruments that includes
two (2) EZ instruments for DNA isolation, three (3) thermal cyclers for amplification and two (2)
Tecan readers for sample detection will save an estimated amount of $10,000.00 per year for
preventive maintenance cost and other additional expense for other instrumentation problems.
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Turnaround Time (TAT)- GeneXpert Sample processing time is about thirty-two (32)
minutes for each test. Patients sample results are verified each day of testing and are available
within 24 hours compared to the current method that has 4-5 hours of processing time and 5 -7
days TAT.
Personnel Utilization and Risk of Injury- With the GeneXpert technology system, it
utilizes only one (1) CLS equivalent to a 0.5 FTE who is performing a two (2) step process
involving sample pipetting, dispensing into the cartridge and then loading it directly into the
instrument module. With the current PCR method, the processing time is 4-6 hours requiring a
1.0 FTE. The process involves multiple users to perform the tests with three (3) different
instruments causing an increased risk of personal injury due to a repetitive range of motion and
potential manual entry errors that may affect patient management. Summary of comparison
between GeneXpert and current method are detailed in a table form. (Table 8)
TABLE 8 COMPARISON OF GENEXPERT VS CURRENT PCR METHOD

Comparison
Actual sample DNA
Isolation/
DNA
Amplification/Detection
Reporting
Pipetting
Instrument used
Personnel needed
Turnaround time (TAT)
Staff injury (Repetitive
pipetting)
Preventive Maintenance (# of
instruments)

GeneXpert Technology
Not performed, occurs inside
the kit
Performed within the
cartridge kit
Manually entered, interpreted
and verified
2 step pipetting
1
0.5 FTE /shift
24 hrs
Decreased/ rare

Current PCR Method
30 minutes per sample

Result automatically transmit
and batch verified
12 step pipetting
3
1.0 FTE/shift
5 – 7 days
Increased/ high probability

1 instrument per year

7 instruments per year

4.5 hours
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DISCUSSION
Thrombophilia is defined as an increased risk or tendency to develop blood clots as a
result of predisposing factors that may be inherited or acquired. It is usually related to the
abnormality of the clotting system of some individuals causing DVT or pulmonary embolism.
The determination of both Factor V Leiden and PT20210 mutation using GeneXpert technology
gives molecular testing a different perspective from usual standard PCR testing. The test is
moderately complex, but the assay is a simple 2 step process that it can be performed by
personnel with less background in molecular testing. It is a fast, single test assay that eases
workflow and delivers same day test results to the clinicians. The technology allows flexibility to
perform other tests for the benefit of better patient management and treatment.
With the approval of the laboratory medical director for the IQCP implementation, the
risk assessment analysis reinforces the accuracy of test results thru the detection of possible
sources of error throughout the three (3) phases of testing. It is enhanced by a customized quality
control plan and a comprehensive quality assessment that will be reviewed and monitored as
indicated in the QC and QA summary. All necessary corrective action will be applied and
implemented to mitigate prevent failures and probable sources of error.
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CONCLUSION
Given its heterogeneity of clinical expressions and still lack of gold standard of testing,
the Cepheid GeneXpert technology will improve the management of individuals who have the
greatest probability of having venous thromboembolism caused by the genetic mutations of
Factor V Leiden and PT20210 variants. Result turnaround time is reduced to 24hrs, prevents
potential staff injury from repetitive motion and promote cost saving for labor and instrument
maintenance.
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